CRLF2 overexpression
|
B Acute Lymphoblastic Leukemia
|
CRLF2 overexpression
|
B Acute Lymphoblastic Leukemia
|
inotuzumab ozogamicin Sensitive: C3 – Early Trials
|
inotuzumab ozogamicin Sensitive: C3 – Early Trials
|
CRLF2 overexpression
|
B Acute Lymphoblastic Leukemia
|
CRLF2 overexpression
|
B Acute Lymphoblastic Leukemia
|
blinatumomab Sensitive: C3 – Early Trials
|
blinatumomab Sensitive: C3 – Early Trials
|
CRLF2 overexpression
|
B Acute Lymphoblastic Leukemia
|
CRLF2 overexpression
|
B Acute Lymphoblastic Leukemia
|
blinatumomab + inotuzumab ozogamicin Sensitive: C3 – Early Trials
|
blinatumomab + inotuzumab ozogamicin Sensitive: C3 – Early Trials
|